TSOI DD Pack
Extremely favorable float with only 46 Million shares available.
Market Value: $5,454,757 a/o Nov 01, 2017
Authorized Shares 990,000,000 a/o Jul 07, 2017
Outstanding Shares 779,251,000 a/o Aug 14, 2017
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 46,317,028 a/o Jul 07, 2017
Par Value 0.001
Therapeutic Solutions International, Inc. is involved in the medical sciences market. We are focused on three different areas within the same market. They are outlined as follows:
1. Dietary Supplements
2. Immunotherapy, and
3. Fetal – Maternal Health
Our business plan is twofold:
1. Produce and refine current product lines and develop them further, and
2. To focus on leveraging immunological processes to diagnose and intervene in niche areas of unmet medical needs.
Recent company updates here:
Major Patent news here: https://ih.advfn.com/p.php?pid=nmona&article=75866660
Sandbox Dental Labs , Inc.
– is a majority owned subsidiary of TSI consisting of a dental laboratory to manufacture and fill prescriptions from dentists who will use our proprietary Sleep Appliance to treat their patients with mild to moderate obstructive sleep apnea.
Emvolio , Inc .
– is a majority owned subsidiary of TSI where the intellectual property surrounding immune-oncology is housed. The Company is developing products that can be used together to attack cancer at different levels, as well as to be used alone or in combination with existing therapies.
Omnibiome , Inc .
– is a majority owned subsidiary of TSI where the intellectual property surrounding probiotics is housed. Current programs focus on the use of probiotics to prevent pre-term labor and on using probiotics to reverse periodontal disease.
– TSI has been producing very high quality nutraceuticals. Its flagship product, Projuvenol®, is a Patented (No. 9,682,047) proprietary mixture containing pterostilbene – one of the most potent antioxidants known.
Timothy G. Dixon – President, CEO, & Chairman
Mr. Dixon currently serves as Chief Executive Officer, President, and Chairman of Therapeutic Solutions International, Inc. Mr. Dixon also serves as President and Chairman of OmniBiome, Inc. and President and Chairman of Emvolio, Inc. Mr. Dixon previously served as the President of TMD Courses, Inc. from 2006 to 2012 and; as the President of Splint Decisions Inc. from 2010 to 2011.
Mr. Dixon has attended hundreds of hours of continuing medical/dental education throughout the years and has produced many educational DVD’s used by dental professionals worldwide on the subject of parafunctional control, migraine prevention, therapeutic Botox injections, migraine pathophysiology, dental sleep medicine, and other therapeutic protocols. Mr. Dixon also has extensive experience in dealing with corporate compliance matters with the U.S. Food and Drug Administration, (FDA) as well as many international regulatory bodies.
Gerry B. Berg – Vice President, CFO, Director
Gerry B. Berg has served as our Vice-President and Chief Financial Officer since April 20, 2011. Mr. Berg also serves as Chief Financial Officer and Director of OmniBiome, Inc. and Chief Financial Officer and Director of Emvolio, Inc. Mr. Berg became a director of the Company on August 24, 2012. Mr. Berg has over 30 years of senior management experience working with private and public companies. From May 2010 to March 2011, Mr. Berg served as President and Chairman of the Board of Directors of Friendly Auto Dealers, Inc., and also served in a consulting capacity from March 2009 to May 2010.
Mr. Berg holds a Bachelors of Science in Accounting from Walsh College where he graduated Cum Laude. Mr. Berg became a Certified Public Accountant in the State of Michigan in 1979 and in the State of California in 1984. Mr. Berg does not currently practice as a Certified Public Accountant.
Thomas E. Ichim, Ph.D – Director
Dr. Ichim was appointed to the Board of Directors on January 22, 2016. Dr. Ichim also serves as Chief Executive Officer of Emvolio, Inc. Dr. Ichim is a seasoned biotechnology entrepreneur with a track record of scientific excellence. He has founded/co-founded several companies including Batu Biologics, Inc., Medvax Pharma Corp, ToleroTech Inc, bioRASI, and OncoMune LLC. To date he has published 99 peer-reviewed articles and is co-editor of the textbooks “RNA Interference: From Bench to Clinical Translation” and “Immuno-Oncology Text Book.”
is an ad-hoc editor and sits on several editorial boards. Dr Ichim is inventor on over 50 patents and patent applications. Dr. Ichim has extensive experience with stem cell therapy and cellular product development through FDA regulatory pathways. Dr. Ichim spent over 7 years as the President and Chief Scientific Officer of Medistem, developing and commercializing a novel stem cell, the Endometrial Regenerative Cell, through drug discovery, optimization, preclinical testing, IND filing, and up through Phase II clinical trials with the FDA. Dr. Ichim has extensive experience in product development, regulatory filings, and business development.
Dr. Ichim has a BSc in Biology from the University of Waterloo, Waterloo, Ontario, Canada, a MSc in Microbiology and Immunology a University of Western Ontario, London, Ontario, Canada and a Ph.D in Immunology from the University of Sciences Arts and Technology, Olveston Monserrat.
Hong Ma, MD, Ph.D., M.B.A. – Chief Scientific Officer
Dr. Ma has an extensive history in academic and translational research. Subsequent to completing her medical degree, she performed basic research in the area of molecular biology of endothelial-associated pathways in her doctorate and postdoctoral studies. She has been critical in establishing numerous ventures and collaborations in the area of biosciences. Dr. Ma has over 20 peer-reviewed publications and has worked with prestigious institutions in the USA, China, and Japan. She received her M.D. from Dalian Medical University, her Ph.D in Cardiovascular Pharmacology at Asahikawa Medical College, and has also earned her MBA at the Rady School of Management at the University of California San Diego.
The level 2 on TSOI is really thin which means it can move very quick! This should be trading in the multi penny area considering all of their patents and assets. The company is pink current as well which is a big bonus. We think this is a great play if you are looking for a solid micro cap play.
Keep an eye out for BTCS as bitcoin continues to climb and may crack 7,000 this week.
Stocks to watch:
BTCS, GHAV, TLUF, SWHI
DISCLAIMER: We do not accept any responsibility for the accuracy of the information and you make your own investment decisions! The information provided is done by our fellow associates and we do not take responsibility or reliability for its accuracy. Please do your own research before entering into a highly volatile company, you could lose the entire sum of you investment. We accept no liability for your investments.